New cancer clinical trial: Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

Published on: November 29, 2017 at 10:00AM
Conditions:   Breast Cancer;   Triple Negative Breast Cancer;   Luminal B
Interventions:   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Durvalumab
Sponsors:   Grand Hôpital de Charleroi;   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Recruiting
http://ift.tt/2Ah85dg